Apnea in the Current Era: Diagnostics, Therapeutics, Adherence is organized by eMedEvents. Description: This webinar will discuss how to help OSA patients remain compliant with their therapy during this time of transition. What should be taken into account: most recent PAP interface technologies, PAP adherence strategies, and should we consider alternative and multimodality therapies? For our patients to remain compliant with their sleep therapy, we may need to change and or combine treatments. Educational Objectives: Addressing the knowledge gap for the changes occurring in diagnosing and treating sleep-disordered breathing in the time of Covid-19. Review of the adherence strategies and technological advances available for addressing compliance issues with PAP therapy. Introducing the concept of multimodality and alternative therapeutics in the treatment of sleep-disordered breathing. Continuing Education for Physicians:   This educational activity is approved for 1 CME contact hour for physicians. The link to obtain CME credits will be provided at the conclusion of the webinar. Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of SynAptiv and eMedEvents. SynAptiv is accredited by the ACCME to provide continuing medical education for physicians.SynAptiv designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Continuing Education for Nurses and Respiratory Therapists:   This educational activity is approved for 1 contact hour for Nurses and RTs. The link to obtain CE credits will be provided at the conclusion of the webinar. Accreditation Statement: Synaptiv is accredited as a provider for continuing education. Provider approved by California Board of Nursing. Provider #14477  and the Florida Board of Nursing Provider # 50-17032. This program has been approved for 1.0 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care, 9425 N. MacArthur Blvd. Suite 100, Irving, TX 75063.  

Oxygen Therapy: What you need to know to get it right for your patients. This webinar discusses evaluation and testing requirements for Long Term Oxygen Therapy (LTOT) treatment, documentation guidelines for writing the proper prescription, considerations regarding matching the right oxygen delivery system to the clinical and lifestyle needs of the patient, as well as, identifying the gaps that contribute to poor adherence to long term oxygen therapy and recommendations for possible solutions. Educational Objectives: List the methods for evaluating the need for Long Term Oxygen Therapy (LTOT), and qualifying a patient for home oxygen coverage.  How to write a proper oxygen prescription. Match the oxygen delivery system to meet the clinical and lifestyle needs of the patient. Identify the gaps that contribute to poor adherence to long term oxygen therapy and list possible solutions. Continuing Education for Physicians:  This educational activity is approved for 1 contact hour for Physicians. The link to obtain CME credits will be provided at the conclusion of the webinar. Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provider ship of SynAptivand eMedEvents. SynAptivis accredited by the ACCME to provide 1 AMA PRA Category 1 Credit™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing Education for Nurses and Respiratory Therapists: This educational activity is approved for 1 contact hour for Nurses and RRTs. The link to obtain CE credits will be provided at the conclusion of the webinar. Accreditation Statement: Synaptivis accredited as a provider for continuing education. Provider approved by California Board of Nursing. Provider #14477and the Florida Board of Nursing Provider # 50-17032.This program has been approved for 1.0 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care, 9425 N. MacArthur Blvd. Suite 100, Irving, TX 75063.      

Sleep Medicine in 2020 and Moving Forward is organized by eMedEvents. Description: This webinar will discuss the changes in sleep medicine during the COVID-19 pandemic. In the future, what should be considered when testing, diagnosing, and treating our sleep patients? What new methods and therapies are being prescribed? Will these changes stay beyond 2020? Educational Objectives: Review some changes in the clinical practice of sleep medicine that have occurred due to COVID-19. Discuss alternate patient care models. Examine some strategies to mitigate COVID-19 risks. Explore the abundance of opportunities available to improve the sleep health of our communities. Continuing Education for Physicians: This educational activity is approved for 1 contact hour for Physicians. The link to obtain CME credits will be provided at the conclusion of the webinar. Accreditation Statement:  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of SynAptiv and eMedEvents. SynAptiv is accredited by the ACCME to provide continuing medical education for physicians. SynAptiv designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Continuing Education for Nurses and Respiratory Therapists:   This educational activity is approved for 1 contact hour for Nurses and RTs. The link to obtain CE credits will be provided at the conclusion of the webinar. Accreditation Statement: Synaptiv is accredited as a provider for continuing education. Provider approved by California Board of Nursing. Provider #14477  and the Florida Board of Nursing Provider # 50-17032. This program has been approved for 1.0 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care, 9425 N. MacArthur Blvd. Suite 100, Irving, TX 75063.  

Bringing Precision Medicine to Cholangiocarcinoma With Mitesh J. Borad, MD is organized by i3 Health. Release Date: October 21, 2020 Expiration Date: October 20, 2021 Accreditation: Physicians i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.  MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Statement of Need: With an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this episode of Oncology Data Advisor, Mitesh J. Borad, MD, Associate Professor of Medicine and Director of the Liver and Biliary Cancer Research Program at the Mayo Clinic Cancer Center in Phoenix, Arizona, joins i3 Health for a discussion that covers the efficacy and adverse events of FGFR inhibitor therapy, ongoing research related to additional therapeutic targets, and the increasing role of precision medicine in the treatment of patients with cholangiocarcinoma. Learning Objectives: Upon completion of this activity, participants should be able to: • Account for tumor genomic factors when determining treatment for patients with cholangiocarcinoma • Identify and manage toxicities from FGFR inhibitor therapy in patients with cholangiocarcinoma Faculty: Mitesh J. Borad, MD  Associate Professor of Medicine Mayo Clinic College of Medicine

Optimizing Patient Outcomes in Pancreatic Cancer With Al B. Benson, MD, FACP, FASCO is organized by i3 Health. Release: August 20, 2020 Expiration: August 19, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Description: With 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches, therapeutic options remain limited. In this episode of Oncology Data Advisor, Al B. Benson, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and Associate Director for Cooperative Groups at Northwestern’s Robert H. Lurie Comprehensive Cancer Center, joins i3 Health for a discussion that covers recent developments in genomic testing and targeted therapies, supportive care measures that can optimize quality of life, and strategies that members of the cancer care team can utilize to improve the outcomes of their patients with pancreatic cancer. Learning Objectives: Upon completion of this activity, participants should be able to: • Identify the role that biomarkers can play in predicting therapeutic efficacy and developing tailored approaches to treatment • Develop effective multidisciplinary approaches that can be used to enhance pancreatic cancer treatment and supportive care https://www.i3health.com/oda-pancreatic Faculty: Al B. Benson, MD, FACP, FASCO, Professor of Medicine, Northwestern University Feinberg School of Medicine

Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD is organized by i3 Health. Release: September 18, 2020 Expiration: September 17, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Description: An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL. Learning Objectives: Upon completion of this activity, participants should be able to: • Assess efficacy and safety of novel BTK inhibitor therapy for MCL • Assess efficacy and safety of CAR T-cell therapy for MCL Faculty: Gilles Salles, MD, PhD Chief of the Lymphoma Service Memorial Sloan Kettering Cancer Center

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes is organized by i3 Health. Release: May 21, 2020 Expiration: May 20, 2021 Accreitation: Physicians: • i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  • Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this program. Nursing Continuing Professional Development: • A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses. • Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour. Statement of Need: Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusions. Approximately 30% of patients with MDS progress to acute myeloid leukemia (AML). The estimated annual age-adjusted incidence of MDS in the United States is 3 to 4 cases per 100,000 individuals, with approximately 14,011 new cases per year. Considering the aging population, the incidence of MDS will likely grow in persons older than 60 years of age. Learning Objectives: Upon completion of this activity, participants should be able to: • Assess patient and tumor characteristics that can inform personalized care plans for patients with MDS • Differentiate emerging data and guideline recommendations on therapeutic approaches for lower- risk, higher-risk, and therapy-related MDS • Evaluate supportive care strategies that can help patients with MDS achieve their goals of cancer therapy Faculty: • David P. Steensma, MD, FACP, Senior Physician, Dana-Farber Cancer Institute • Reza Nejati, MD, Associate Professor, Department of Pathology, TUHS-Fox Chase Cancer Center • Ilene Galinsky, BSN, MSN, ANP-C, Nurse Practitioner, Dana-Farber Cancer Institute

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Advanced Soft Tissue Sarcoma is organized by i3 Health. Release Date: October 30, 2020 Expiration Date: October 29, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.75 hours of Category 1 credit for completing this program. Nursing Continuing Professional Development: A maximum of 0.75 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses. Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.75 contact hour. Statement of Need: Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. An estimated 13,130 new cases are diagnosed in the United States annually and 5,350 people die of the disease. Surgical resection is the mainstay of treatment for localized soft tissue sarcoma, with radiation and chemotherapy commonly used as adjuncts. However, nearly 50% of patients will experience locoregional recurrence, distant metastases, or both. The outlook for those with unresectable and metastatic disease is poor, with median overall survival in the order of 1 year. Learning Objectives: ​​​​Upon completion of this activity, participants should be able to: • Distinguish patient and tumor characteristics that can inform personalized therapeutic approaches in soft tissue sarcoma • Evaluate the clinical relevance of emerging data in the management of advanced soft tissue sarcoma • Assess strategies to manage adverse events and optimize treatment outcomes of patients with advanced soft tissue sarcoma Faculty: • Vicki L. Keedy, MD, MSCI (Chairperson) Associate Professor of Medicine Clinical Director, Sarcoma Vanderbilt-Ingram Cancer Center • Brian P. Rubin, MD, PhD Institute Chairman Robert J. Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic • Kathleen Polson, NP Nurse Practitioner Dana-Farber Cancer Institute

Transforming Mammography: Current & Future Practice Considerations of Digital Breast Tomosynthesis is organized by World Class CME. Release Date: 5/5/2020 Expiry Date: 6/1/2023 Accreditation: World Class CME is authorized by the Accreditation Council for Continuing Medical Education to accommodate continuing medical education for physicians. World Class CME assigns this enduring Online CME material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians can acquire credit commensurate based on the extent of their participation in the activity. The American Society of Radiologic Technologists has recommended this activity for Category A CE credits as follows. The American Registry of Diagnostic Medical Sonographers (ARDMS) allows all American Society of Radiologic Technologists (ASRT) Category A credits to fulfill their necessities for continuing education (CE) credits. Upon completion of this lecture, participants will be able to: •  Know the difference between Full Field Digital Mammography (DM) and Digital Breast Tomosynthesis (DBT), including DM limitations •  Know why DBT has become a transformative technology in breast cancer detection and decrease of recall rate •  Visually recognize how DBT can be beneficial in the disclosure of subtle mammographic lesions and architectural distortion in comparison to DM through case examples.

Florida Law for Nurses 2018 is organized by Anderson Continuing Education. Expiration Date: 12/31/2020 Conference Description : The purpose of this course is to comply with a Florida Board of Nursing rule requiring nurses licensed in Florida to complete a 2-hour course on the laws and rules that govern the practice of nursing each renewal cycle. These laws and rules include the scope of practice of registered nurses, licensed practical nurses, certified nursing assistants, as well as advanced nursing practice. In addition, the course covers continuing education requirements, CE Broker reporting, and disciplinary action against nurses' licenses. The course includes numerous judicial decisions decided within the last five years in which nurses were disciplined. These are actual cases involving nurses licensed in Florida. Additional details will be posted as soon as they are available.